DALLAS, May 12, 2022
/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a
clinical stage biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") and machine
learning (ML) platform to transform the cost, pace, and timeline of
oncology drug discovery and development, today announced that it
will host a virtual key opinion leader (KOL) webinar on
May 26th, 2022 at
12:00 p.m. ET. The webinar will focus
on glioblastoma multiforme (GBM) and the potential of Lantern's
drug candidate LP-184 for GBM as well as other brain cancers.
The webcast will feature discussions by two leading experts in
GBM and brain cancer treatment and research: John Laterra, M.D., Ph.D. and Matthias Holdhoff,
M.D., Ph.D. They will be accompanied by Lantern's Chief Scientific
Officer, Kishor Bhatia, Ph.D. who
will describe the clinical development plans for LP-184 as well as
the mechanisms targeted by LP-184 in GBM and other brain cancers.
Following their discussion, there will be a live question and
answer session with Dr. Bhatia.
Virtual KOL Webinar Details:
- Thursday, May 26th,
2022 at 12:00 p.m. – 1:00 p.m. ET
- To register for the webinar, please use the link
below:
https://us06web.zoom.us/webinar/register/5116517778233/WN_0HqKxJ9uT6Gy5h3ycoZD1Q
- A replay of the webinar will be available on Lantern's website
beginning on May 27th:
www.lanternpharma.com
About Brain Cancer Awareness Month:
This KOL webinar
will be hosted during Brain Tumor Awareness Month, which is also
known as "Gray May". This month is
meant to bring support and awareness to the estimated 700,000
people in the US living with primary brain tumors and to their
families and caregivers. Patients with primary brain tumors have a
low 5-year survival rate of only 35.6% and have limited treatment
options due to the lack of effective drugs that can cross the blood
brain barrier. For more information, please visit the Brain Tumor
Awareness month website.
GBM is one of the most common types of primary brain tumors with
an estimated 13,000 people in the US diagnosed each year. Patients
with GBM have a very poor prognosis with a median overall survival
of 24 months. The low survival rate of patients with GBM is in part
due to the lack of effective new therapies that can cross the blood
brain barrier (BBB) and there is an urgent and unmet clinical need
for new therapies. In preclinical studies, Lantern's drug
candidate, LP-184, has shown potency against unmethylated and
methylated types of GBM as well as the ability to cross the
BBB.
About Dr. John Laterra
Dr. Laterra is an internationally recognized researcher in
neurology, oncology, and neuroscience. He serves as the Director of
the Brain Cancer Program and the Director of the Division of
Neuro-Oncology at Johns Hopkins School of
Medicine where he specializes in investigating mechanisms of
brain tumor malignancy, tumor vascular biology, and identification
of new therapeutic targets in gliomas. Dr. Laterra received his
Ph.D. in microbiology and M.D. from Case
Western Reserve University. He served as a resident and
chief resident in neurology at the University
of Michigan at Ann Arbor. Dr. Latera joined Johns Hopkins and the Kennedy Krieger Institute in
1988.
About Dr. Mattias Holdhoff:
Dr. Holdhoff is a medical
neuro-oncologist in the Brain Cancer Program at the Sidney Kimmel
Comprehensive Cancer Center at Johns
Hopkins, as well as an associate professor of oncology and
neurological surgery at Johns Hopkins
University School of Medicine. Dr. Holdhoff's clinical and
research expertise is in primary brain cancers, malignant gliomas,
and central nervous system lymphomas. He received his Ph.D. at
Charité University Medicine Berlin and his M.D. from Freie
Universität Berlin. Dr. Holdhoff
completed his residency in internal medicine at Johns Hopkins
Bayview Medical Center, followed by a fellowship in medical
oncology at Johns Hopkins Hospital.
About Lantern Pharma:
Lantern Pharma (NASDAQ:
LTRN) is a clinical-stage oncology-focused biopharmaceutical
company leveraging its proprietary RADR® A.I. and
machine learning platform to discover biomarker signatures that
identify patients most likely to respond to its pipeline of
genomically targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across nine disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes.
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma
Lantern's Investor Relations Contact:
Nicole Leber
Investor Relations Associate
ir@lanternpharma.com
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA
marketing approval or otherwise been incorporated into a commercial
product, and (v) those other factors set forth in the Risk Factors
section in our Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the
Securities and Exchange Commission on March
10, 2022. You may access our Annual Report on Form 10-K for
the year ended December 31, 2021
under the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov. Given
these risks and uncertainties, we can give no assurances that our
forward-looking statements will prove to be accurate, or that any
other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-host-virtual-kol-event-on-glioblastoma-multiforme-gbm-with-collaborators-from-johns-hopkins-during-brain-tumor-awareness-month-301545669.html
SOURCE Lantern Pharma